Close Menu

NEW YORK – Exact Sciences reported after the close of the market on Tuesday that its fourth quarter revenues rose 107 percent year over year, thanks to a 63 percent increase in testing volumes for its Cologuard colorectal cancer screening test.

For the three months ended Dec. 31, 2019, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $295.6 million, up from $143.0 million a year earlier, and beating the average Wall Street estimate of $283.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.